Core Insights - The Jiangsu Provincial Health Cloud Clinical Testing Platform enhances patient convenience by allowing seamless access to medical test results across different healthcare institutions [1][2] - The platform has significantly improved the efficiency of medical diagnostics and reduced the burden on patients by eliminating the need for repeated tests [1][2] Group 1: Platform Overview - The Jiangsu Health Cloud Clinical Testing Platform was initiated in August 2024 and has integrated with 1,867 medical institutions by September 2025 [2] - The platform has uploaded 252 million patient test reports and facilitated 15.62 million doctor queries and 1.56 million resident queries [2] - A total of 2.95 million test result recognitions have been achieved, allowing for "one-screen viewing and one-click recognition" of test results [2] Group 2: Benefits to Patients - The platform allows for quicker medical responses, as demonstrated by a case where a patient underwent a critical procedure within 37 minutes of arrival at the hospital due to pre-existing test results [1] - Over the past year, the platform has facilitated 24,000 test result recognitions at a local hospital, saving patients over 300,000 yuan in medical costs [1] Group 3: Quality Control Measures - To ensure the platform's effective operation, the Jiangsu Provincial Health Commission has established quality control standards and operational guidelines for recognized test projects [2] - A comprehensive quality control system has been implemented across the province to manage participating institutions and ensure the accuracy and reliability of data [2]

Group 1 - The core viewpoint is that the in vitro diagnostic industry is facing unprecedented challenges due to intensified competition and various policy reforms, including the continuous promotion of centralized procurement and the rapid implementation of DRG [2] - The company is actively optimizing human resource costs as part of its strategy to reduce expenses and enhance efficiency in response to market and policy challenges [2] - The company is committed to improving its operational performance and increasing its intrinsic value amidst the evolving industry landscape [2]

Core Viewpoint - The company held an online performance briefing on May 27, 2025, to discuss its 2024 annual and 2025 Q1 performance, addressing investor concerns and highlighting operational and financial conditions [1]. Group 1: Financial Performance - The company's gross margin for 2024 increased by 2.86 percentage points to 69.23%, attributed to supply chain management optimization and product structure adjustments, despite a decline in operating revenue [2]. - In Q1 2025, the company achieved operating revenue of 244 million yuan, with overseas conventional product revenue reaching 47 million yuan, a year-on-year increase of 66.51% [2]. Group 2: Business Strategy and Market Position - The company is responding to industry challenges such as centralized procurement and DRG policies by optimizing sales strategies and enhancing service systems to maintain stable business development [4]. - The Metis6000 fully automated biochemical immunoassay line targets secondary and lower-tier hospitals, with over 70% of installations in these facilities, indicating a clear market positioning strategy [4][5]. Group 3: Product Development and Innovation - The Metis7000 fully automated biochemical immunoassay line is in the trial production phase, aiming to enhance performance and cost-effectiveness, with a broad testing menu covering nearly 400 items [5]. - The company plans to further increase the proportion of its chemiluminescence business, which accounted for 26.72% of self-produced product revenue in 2024, growing by 31.14% year-on-year [4]. Group 4: International Expansion - The company has established a presence in 66 countries and regions, holding over 2,500 overseas registration certificates and product import permits, with a focus on expanding its market share in Europe, Asia, and Latin America [5].